Habteab Feseha, MD
Cardiology · Yuma, AZNPI 1679665517
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $12,806 of the $17,803 with a category attached, or 71.9%. Medtronic accounts for 70.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $11,807 and has fallen 95.9% since, to $486 in 2025.
Across 131 payments — averaging $135.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$13K
- Boston Scientific$3K
- Abiomed$2K
- Edwards Lifesciences$442
- Endologix LLC$274
- Abbott$43
- plus $61 from 2 others
Across 1 payment — averaging $35,834 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$36K
What the payments were for
- Travel & lodging$12,80672%
- Food & beverage$4,99728%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 76 | $12,502 |
| Boston Scientific | 28 | $2,865 |
| Abiomed | 14 | $1,617 |
| Edwards Lifesciences | 5 | $442 |
| Endologix LLC | 3 | $274 |
| Abbott | 2 | $43 |
| Chiesi USA, Inc. | 2 | $38 |
| Amgen | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few cardiology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 348 | $442,243 |
| EntrestoSacubitril/Valsartan | 124 | $154,580 |
| XareltoRivaroxaban | 57 | $59,217 |
| BrilintaTicagrelor | 18 | $20,734 |
| JardianceEmpagliflozin | 13 | $20,536 |
| Repatha SyringeEvolocumab | 22 | $18,294 |
| Repatha PushtronexEvolocumab | 20 | $11,962 |
| Repatha SureclickEvolocumab | 18 | $11,932 |
| Carvedilol | 928 | $11,463 |
| Losartan Potassium | 558 | $8,749 |
| Atorvastatin Calcium | 435 | $7,733 |
| ClopidogrelClopidogrel Bisulfate | 341 | $6,351 |
| Metoprolol Succinate | 304 | $6,252 |
| Lisinopril | 451 | $5,661 |
| Amlodipine Besylate | 458 | $5,191 |
Paid to pharmacies, not to this prescriber.
Other cardiology in Yuma
- Maher AwarYuma$5K
- Tri NguyenPhoenix$12K
- Paul DuongPhoenix$11K
- Nitin PatelPrescott Valley$2K
- Douglas RothrockPrescott$156
- Frederick SimonieScottsdale$74
- Carolyn LarsenScottsdale$0
- Susan Wilansky MarkowitzScottsdale$0
- Gerald WolffTucson$0
- Abdul TajikScottsdale$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.